Telomir Pharmaceuticals To Present At BIO 2025, Eyes IND Filing For Telomir-1

June 03, 2025 04:57 AM AEST | By EODHD

Google News:

Telomir Pharmaceuticals To Present At BIO 2025, Eyes IND Filing For Telomir-1 — Image source: Kalkine Media

Recent News

What are next big copper projects? UBS tells when equipment makers cou...

EUR/USD poised to rack up more gains as ECB and Fed rate paths set to...

Carney launches ‘One Canadian Economy’ Act to unify trade, approvals

Trump signs orders to enhance drone defenses, support supersonic trave...

(RTTNews) - Telomir Pharmaceuticals, Inc. (TELO), announced its participation in the BIO International Convention 2025, taking place June 16-19 in Boston, as the company advances toward submitting an Investigational New Drug or IND application for Telomir-1, its lead anti-aging small molecule candidate. The company plans to begin first-in-human dosing in the first half of 2026, following a pre-IND meeting with the FDA. Telomir-1 is a novel oral small molecule designed to elongate telomeres, regenerate cells, and reverse biological aging. The candidate is also being evaluated for use in rare diseases, including Werner's syndrome, Wilson's disease, Progeria, and certain forms of dysphonia, with plans to establish novel clinical endpoints in consultation with the FDA.

Beyond rare diseases, Telomir has reported preclinical success for Telomir-1 in conditions such as autism spectrum disorder, type 2 diabetes, age-related macular degeneration, and aggressive prostate cancer. A separate anti-infective candidate, Telomir-Ag2, has shown promising activity against multidrug-resistant bacteria, including MRSA. "We see Telomir-1 not just as a treatment but as a platform with transformative potential across aging-related diseases," said CEO Erez Aminov. The company will engage in BIO One-on-One Partnering meetings during the event to explore licensing, collaboration, and M&A opportunities. Currently, TELO is trading at $2.09, up by 7.71 percent on the Nasdaq.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.